Page 103 - MemoriaEHD-Eng

www.ciberehd.org

• L a, B M, N J. Gastrointestinal events in at-risk patients starting non-
Most relevant aNasoersuevo
steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE
scientific study of European routine practice.Ann Rheum Dis. 2013 Dec 18;.

articles
• B L, L á, Q e, C a, s C, C J. Effect of aspirin and
uJaNDaaNasuiNteroasteLLsarasQuetauBieLLa
antiplatelet drugs on the outcome of the fecal immunochemical test.Mayo Clin Proc.
2013 Jul;88(7):683-9.

• L a, p-t M, C-a r. The aspirin cardiovascular/gastrointestinal
aNasoLooMásasaDorroyo
risk calculator--a tool to aid clinicians in practice.Aliment Pharmacol Ther. 2013
Apr;37(7):738-48.

• L a. Compliance with prescriptions of appropriate therapy for nonsteroidal anti-
aNas
inflammatory drug users: is the glass half empty or half full?Clin Gastroenterol He-
patol. 2013 May;11(5):505-6.

• g F, g Jp. Current management of iron deficiency anemia in inflam-
oMoLLóNisBert
matory bowel diseases: a practical guide.Drugs. 2013 Nov;73(16):1761-70.
ñó

ó

PROJECTS
á
Highlights
ó
•AngelLanas. Evaluationoftheeffectivenessofflavodixininhibitorsintheeradicationof
í
helicobacter pylori infection in an experimental animal model in m. gerbils. PI11/02578
Á
• ó
AsuncinGarca.PS09/00213. RelevanceofDNArepairgenepolymorphismsasgenetic
markes of susceptibility and /or prognosis of gastric adenocarcinoma.. Their interaction
ó
with environmental factors and Helicobacter pylori infection.
•
Elena Piazuelo. PI11/02089. Epigenetic changes in the progression of Barrett’s esopha-
gus to esophageal adenocarcinoma: aplication to the identification of high risk patients

•AngelFerrndez. PI10/02934. Follow-upstudyoffactorsassociatedwithprogressiónof

preneoplastic lesions of gastric cancer.
•FernandoGomolln. Europeanproject. InflammatoryBowelDiseaseCHARACTERization

byamulti-modalintegratedbiomarkerstudy. Projectacronym:IBD-CHARACTER, Grant
agreement no: 305676.

CLINICAL TRIALS

•ClinicalPharmacologyofenteric-coatedaspirininhealthysubjects. AngelLanas. PhaseI.

•MelatoninassociatedtoacidinhibitionforchemopreventioninBE:apilotstudy. Angel

Lanas. Phase IV.
•
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group,
Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety

andTolerabilityofLocallyAppliedNRL001Overan8WeekTreatmentPeriod. Federico
Sopea. Phase II.

TOOL WITH INTELECTUAL PROPERTY OF CLINIC USE

http://www.asariskcalculator.com
13
CLINICAL GUIDELINES
20
T
• [Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consen- OR
sus document ellaborated by nominated experts of three scientific associations (SER-SEC- P
RE
AEG)]. Lanas A, et al. . Gastroenterol Hepatol. 2014 Mar;37(3):107-27
L
A
• [Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative NU
Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Ca- N
A
briada JL, ....., Gomolln F; (GETECCU). Gastroenterol Hepatol. 2013 Mar;36(3):127-46.
D /
H
• [III Spanish Consensus Conference on Helicobacter pylori infection]. Gisbert JP, ..... Go- E
molln F, Lanas , et all. Gastroenterol Hepatol. 2013 May;36(5):340-74..
ER
IB
• Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETEC- C

CU. Gomolln F, et all. Gastroenterol Hepatol. 2013 Feb;36(2):104-14
103